ARTICLE | Company News
Eli Lilly sales and marketing update
December 21, 2015 8:00 AM UTC
Eli Lilly launched lung cancer drug Portrazza necitumumab in the U.S. at a wholesale acquisition cost (WAC) of $8,000 per three-week treatment cycle. Lilly said the company estimates a total treatmen...